In the context of the multi-targets AXL inhibitors currently being developed and widely used in clinical practice [38], our results provide theoretical evidence for a combination therapy including AXL inhibitors to treat integrin β3-positive NSCLC patients receiving EGFR-TKI. Here, EGFR is linked to non-small cell lung carcinoma.